메뉴 건너뛰기
Cancer Management and Research
Volumn 2, Issue 1, 2010, Pages 143-156
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Author keywords

Elotinib; First line; Maintenance; Non small cell lung cancer; Tyrosine kinase inhibitors
Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX;
EID: 77955355467     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/cmar.s5398     Document Type: Review
Times cited : (19)
References (96)
  • 1
    • 0030774045 scopus 로고    scopus 로고
    • Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
    • Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57:4838-4848.
    • (1997) Cancer Res , vol.57 , pp. 4838-4848
    • Moyer, J.D.1    Barbacci, E.G.2    Iwata, K.K.3
  • 2
    • 0032695910 scopus 로고    scopus 로고
    • Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
    • Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999;291:739-748.
    • (1999) J Pharmacol Exp Ther , vol.291 , pp. 739-748
    • Pollack, V.A.1    Savage, D.M.2    Baker, D.A.3
  • 3
    • 0037392444 scopus 로고    scopus 로고
    • Issues and progress with protein kinase inhibitors for cancer treatment
    • Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296-313.
    • (2003) Nat Rev Drug Discov , vol.2 , pp. 296-313
    • Dancey, J.1    Sausville, E.A.2
  • 4
    • 0028955388 scopus 로고
    • Epidermal growth factor-related peptides and their receptors in human malignancies
    • Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
    • (1995) Crit Rev Oncol Hematol , vol.19 , pp. 183-232
    • Salomon, D.S.1    Brandt, R.2    Ciardiello, F.3    Normanno, N.4
  • 5
    • 77955401515 scopus 로고    scopus 로고
    • EPARs for authorised medicinal products for human use, Accessed March 2
    • EPARs for authorised medicinal products for human use, EMEA. http//www.emaeuropaeu/humandocs/Humans/EPAR/tarceva/tarcevahtm Accessed March 2, 2010.
    • (2010) EMEA
  • 6
    • 77955410200 scopus 로고    scopus 로고
    • US Food and Drug Administration, Accessed March 2
    • US Food and Drug Administration, FDA.http//www.accessdatafdagov/cripts/cder/DrugsatFDA/indexcfm?fuseaction=SearchDrugDetails Accessed March 2, 2010.
    • (2010) FDA
  • 7
    • 70350578566 scopus 로고    scopus 로고
    • Optimizing the management of advanced non-small-cell lung cancer: A personal view
    • Vincent MD. Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol. 2009;16:9-21.
    • (2009) Curr Oncol , vol.16 , pp. 9-21
    • Vincent, M.D.1
  • 9
    • 0013594517 scopus 로고    scopus 로고
    • New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
    • Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087-1100.
    • (1998) Clin Cancer Res , vol.4 , pp. 1087-1100
    • Bunn, P.A.1    Kelly, K.2
  • 10
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller JH, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
    • (2002) N Engl J Med , vol.346 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 11
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti G V, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Pawel, J.V.3
  • 12
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 13
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227-1234.
    • (2009) J Clin Oncol , vol.27 , pp. 1227-1234
    • Reck, M.1    von Pawel, J.2    Zatloukal, P.3
  • 14
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
    • Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525-1531.
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 15
    • 84895559882 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Clinical Practice Guidelines Update on Chemotherapy for Stage IV, Accessed March 2
    • American Society of Clinical Oncology Clinical Practice Guidelines Update on Chemotherapy for Stage IV Non-Small Cell Lung Cancer. http//www.ascoorg/guidelines/nsclc. Accessed March 2, 2010.
    • (2010) Non-Small Cell Lung Cancer
  • 16
    • 34248140107 scopus 로고    scopus 로고
    • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
    • Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552.
    • (2007) J Clin Oncol , vol.25 , pp. 1545-1552
    • Gatzemeier, U.1    Pluzanska, A.2    Szczesna, A.3
  • 17
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
    • (2000) J Clin Oncol , vol.18 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3
  • 18
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 19
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 20
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
    • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 21
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 22
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 23
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304: 1497-1500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3
  • 24
    • 68949201629 scopus 로고    scopus 로고
    • Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors
    • Gazdar A F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28 Suppl 1:S24-S31.
    • (2009) Oncogene , vol.28 , Issue.1
    • Gazdar, A.F.1
  • 25
    • 25844457433 scopus 로고    scopus 로고
    • The epidermal growth factor receptor family
    • Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005;12 Suppl 1:S17-S27.
    • (2005) Endocr Relat Cancer , vol.12 , Issue.1
    • Bazley, L.A.1    Gullick, W.J.2
  • 26
    • 43249096031 scopus 로고    scopus 로고
    • Structure and clinical relevance of the epidermal growth factor receptor in human cancer
    • Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26:1742-1751.
    • (2008) J Clin Oncol , vol.26 , pp. 1742-1751
    • Kumar, A.1    Petri, E.T.2    Halmos, B.3    Boggon, T.J.4
  • 27
    • 40849147041 scopus 로고    scopus 로고
    • EGFR antagonists in cancer treatment
    • Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
    • (2008) N Engl J Med , vol.358 , pp. 1160-1174
    • Ciardiello, F.1    Tortora, G.2
  • 28
    • 61749090015 scopus 로고    scopus 로고
    • Deregulated EGFR signaling during lung cancer progression: Mutations, amplicons, and autocrine loops
    • Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res (Phila Pa). 2008;1:156-160.
    • (2008) Cancer Prev Res (Phila Pa) , vol.1 , pp. 156-160
    • Gazdar, A.F.1    Minna, J.D.2
  • 29
    • 0026521394 scopus 로고
    • Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
    • Ekstrand AJ, Sugawa N, James CD, Collins V P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992;89:4309-4313.
    • (1992) Proc Natl Acad Sci U S A , vol.89 , pp. 4309-4313
    • Ekstrand, A.J.1    Sugawa, N.2    James, C.D.3    Collins, V.P.4
  • 30
    • 28844501639 scopus 로고    scopus 로고
    • Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
    • Shigematsu H, Gazdar A F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257-262.
    • (2006) Int J Cancer , vol.118 , pp. 257-262
    • Shigematsu, H.1    Gazdar, A.F.2
  • 31
    • 33746133158 scopus 로고    scopus 로고
    • Biological and clinical implications of EGFR mutations in lung cancer
    • Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006;11:190-198.
    • (2006) Int J Clin Oncol , vol.11 , pp. 190-198
    • Mitsudomi, T.1    Kosaka, T.2    Yatabe, Y.3
  • 32
    • 73449096114 scopus 로고    scopus 로고
    • Frequency of and variables associated with the EGFR mutation and its subtypes
    • Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2010;126:651-655.
    • (2010) Int J Cancer , vol.126 , pp. 651-655
    • Tanaka, T.1    Matsuoka, M.2    Sutani, A.3
  • 33
    • 4143066760 scopus 로고    scopus 로고
    • Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
    • Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
    • (2004) Science , vol.305 , pp. 1163-1167
    • Sordella, R.1    Bell, D.W.2    Haber, D.A.3    Settleman, J.4
  • 34
    • 10844268011 scopus 로고    scopus 로고
    • Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474
    • Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 2004;64:9101-9104.
    • (2004) Cancer Res , vol.64 , pp. 9101-9104
    • Arao, T.1    Fukumoto, H.2    Takeda, M.3    Tamura, T.4    Saijo, N.5    Nishio, K.6
  • 35
    • 28444478439 scopus 로고    scopus 로고
    • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
    • Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2:e313.
    • (2005) PLoS Med , vol.2
    • Greulich, H.1    Chen, T.H.2    Feng, W.3
  • 36
    • 33746933434 scopus 로고    scopus 로고
    • Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    • Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006;12:4416s-4420s.
    • (2006) Clin Cancer Res , vol.12
    • Janne, P.A.1    Johnson, B.E.2
  • 37
    • 23844491524 scopus 로고    scopus 로고
    • Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
    • Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005;97:1185-1194.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1185-1194
    • Mukohara, T.1    Engelman, J.A.2    Hanna, N.H.3
  • 38
    • 33746034167 scopus 로고    scopus 로고
    • Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    • Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908-3914.
    • (2006) Clin Cancer Res , vol.12 , pp. 3908-3914
    • Jackman, D.M.1    Yeap, B.Y.2    Sequist, L.V.3
  • 39
    • 25444505624 scopus 로고    scopus 로고
    • Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
    • Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005;65:8968-8974.
    • (2005) Cancer Res , vol.65 , pp. 8968-8974
    • Jiang, J.1    Greulich, H.2    Janne, P.A.3    Sellers, W.R.4    Meyerson, M.5    Griffin, J.D.6
  • 40
    • 73349096261 scopus 로고    scopus 로고
    • Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2009;15:7502-7509.
    • (2009) Clin Cancer Res , vol.15 , pp. 7502-7509
    • Hammerman, P.S.1    Janne, P.A.2    Johnson, B.E.3
  • 41
    • 33847406095 scopus 로고    scopus 로고
    • Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
    • Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11:217-227.
    • (2007) Cancer Cell , vol.11 , pp. 217-227
    • Yun, C.H.1    Boggon, T.J.2    Li, Y.3
  • 42
    • 73349094018 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors: Similar but different?
    • Rukazenkov Y, Speake G, Marshall G, et al. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs. 2009;20:856-866.
    • (2009) Anticancer Drugs , vol.20 , pp. 856-866
    • Rukazenkov, Y.1    Speake, G.2    Marshall, G.3
  • 44
    • 33847371736 scopus 로고    scopus 로고
    • Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
    • Yuza Y, Glatt KA, Jiang J, et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther. 2007;6:661-667.
    • (2007) Cancer Biol Ther , vol.6 , pp. 661-667
    • Yuza, Y.1    Glatt, K.A.2    Jiang, J.3
  • 45
    • 33746877875 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutation testing in the care of lung cancer patients
    • Sequist LV, Joshi VA, Janne PA, et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006;12:4403s-4408s.
    • (2006) Clin Cancer Res , vol.12
    • Sequist, L.V.1    Joshi, V.A.2    Janne, P.A.3
  • 46
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-967.
    • (2009) N Engl J Med , vol.361 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3
  • 47
    • 69349088824 scopus 로고    scopus 로고
    • Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials
    • Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15: 5267-5273.
    • (2009) Clin Cancer Res , vol.15 , pp. 5267-5273
    • Jackman, D.M.1    Miller, V.A.2    Cioffredi, L.A.3
  • 48
    • 45149084723 scopus 로고    scopus 로고
    • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    • Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442-2449.
    • (2008) J Clin Oncol , vol.26 , pp. 2442-2449
    • Sequist, L.V.1    Martins, R.G.2    Spigel, D.3
  • 49
    • 77955344353 scopus 로고    scopus 로고
    • Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: Pooled analysis
    • Dec 8. [Epub ahead of print]
    • Paz-Ares L, Soulieres D, Melezinek I, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2009 Dec 8. [Epub ahead of print]
    • (2009) J Cell Mol Med
    • Paz-Ares, L.1    Soulieres, D.2    Melezinek, I.3
  • 50
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 51
    • 63049132774 scopus 로고    scopus 로고
    • First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
    • Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394-1400.
    • (2009) J Clin Oncol , vol.27 , pp. 1394-1400
    • Inoue, A.1    Kobayashi, K.2    Usui, K.3
  • 52
    • 67650378948 scopus 로고    scopus 로고
    • Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations
    • Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493-4498.
    • (2009) Clin Cancer Res , vol.15 , pp. 4493-4498
    • Morita, S.1    Okamoto, I.2    Kobayashi, K.3
  • 53
    • 76749137179 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
    • Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol. 2009;22: 112-120.
    • (2009) Curr Opin Oncol , vol.22 , pp. 112-120
    • Rosell, R.1    Viteri, S.2    Molina, M.A.3    Benlloch, S.4    Taron, M.5
  • 56
    • 33745928129 scopus 로고    scopus 로고
    • Smoking history and epidermal growth factor receptor expression as predictors of survival beneft from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
    • Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival beneft from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer. 2006;7:389-394.
    • (2006) Clin Lung Cancer , vol.7 , pp. 389-394
    • Clark, G.M.1    Zborowski, D.M.2    Santabarbara, P.3
  • 58
    • 33750207905 scopus 로고    scopus 로고
    • Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefts in advanced non-small-cell lung cancer
    • von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefts in advanced non-small-cell lung cancer. Br J Cancer. 2006;95:966-973.
    • (2006) Br J Cancer , vol.95 , pp. 966-973
    • von Plessen, C.1    Bergman, B.2    Andresen, O.3
  • 59
    • 0036499649 scopus 로고    scopus 로고
    • Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    • Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20:1335-1343.
    • (2002) J Clin Oncol , vol.20 , pp. 1335-1343
    • Socinski, M.A.1    Schell, M.J.2    Peterman, A.3
  • 60
    • 0024492873 scopus 로고
    • Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study
    • Buccheri GF, Ferrigno D, Curcio A, Vola F, Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer. 1989;63:428-432.
    • (1989) Cancer , vol.63 , pp. 428-432
    • Buccheri, G.F.1    Ferrigno, D.2    Curcio, A.3    Vola, F.4    Rosso, A.5
  • 61
    • 33646485007 scopus 로고    scopus 로고
    • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
    • Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52:155-163.
    • (2006) Lung Cancer , vol.52 , pp. 155-163
    • Brodowicz, T.1    Krzakowski, M.2    Zwitter, M.3
  • 62
    • 36849019938 scopus 로고    scopus 로고
    • Phase III trial of two versus four additional cycles in patients who are no progressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer
    • Park JO, Kim S W, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are no progressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5233-5239.
    • (2007) J Clin Oncol , vol.25 , pp. 5233-5239
    • Park, J.O.1    Kim, S.W.2    Ahn, J.S.3
  • 63
    • 0035281498 scopus 로고    scopus 로고
    • Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
    • Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19:1336-1343.
    • (2001) J Clin Oncol , vol.19 , pp. 1336-1343
    • Smith, I.E.1    O'Brien, M.E.2    Talbot, D.C.3
  • 64
    • 70249130544 scopus 로고    scopus 로고
    • Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials
    • Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27:3277-3283.
    • (2009) J Clin Oncol , vol.27 , pp. 3277-3283
    • Soon, Y.Y.1    Stockler, M.R.2    Askie, L.M.3    Boyer, M.J.4
  • 65
    • 24944440830 scopus 로고    scopus 로고
    • TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    • Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
    • (2005) J Clin Oncol , vol.23 , pp. 5892-5899
    • Herbst, R.S.1    Prager, D.2    Hermann, R.3
  • 66
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1
    • Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004;22:777-784.
    • (2004) J Clin Oncol , vol.22 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3
  • 67
    • 1542713370 scopus 로고    scopus 로고
    • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 2
    • Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004;22:785-794.
    • (2004) J Clin Oncol , vol.22 , pp. 785-794
    • Herbst, R.S.1    Giaccone, G.2    Schiller, J.H.3
  • 68
    • 75249084998 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
    • Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:5080-5087.
    • (2009) J Clin Oncol , vol.27 , pp. 5080-5087
    • Mok, T.S.1    Wu, Y.L.2    Yu, C.J.3
  • 69
    • 59149092945 scopus 로고    scopus 로고
    • Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    • Fidias PM, Dakhil SR, Lyss A P, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:591-598.
    • (2009) J Clin Oncol , vol.27 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3
  • 70
    • 70449348120 scopus 로고    scopus 로고
    • Maintenance therapy in no small-cell lung cancer: A new treatment paradigm
    • Mok TS, Ramalingam SS. Maintenance therapy in no small-cell lung cancer: a new treatment paradigm. Cancer. 2009;115:5143-5154.
    • (2009) Cancer , vol.115 , pp. 5143-5154
    • Mok, T.S.1    Ramalingam, S.S.2
  • 71
    • 62349108713 scopus 로고    scopus 로고
    • The role of maintenance chemotherapy in advanced no small cell lung cancer
    • Jalal SI, Ademuyiwa FO, Hanna NH. The role of maintenance chemotherapy in advanced no small cell lung cancer. Curr Opin Oncol. 2009;21:110-115.
    • (2009) Curr Opin Oncol , vol.21 , pp. 110-115
    • Jalal, S.I.1    Ademuyiwa, F.O.2    Hanna, N.H.3
  • 72
    • 0019952884 scopus 로고
    • Rationale for the use of alternating non-cross-resistant chemotherapy
    • Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982;66:439-449.
    • (1982) Cancer Treat Rep , vol.66 , pp. 439-449
    • Goldie, J.H.1    Coldman, A.J.2    Gudauskas, G.A.3
  • 73
    • 70349475409 scopus 로고    scopus 로고
    • SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
    • Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 2009;27 Suppl 15: 8001.
    • (2009) J Clin Oncol , vol.27 , Issue.15
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 74
    • 70349477817 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastasic non-small cell lung cancer
    • Miller V, O'Connor P, Soh C, et a1. A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastasic non-small cell lung cancer. J Clin Oncol. 2009; 27 Suppl 15:LBA8002.
    • (2009) J Clin Oncol , vol.27 , Issue.15
    • Miller, V.1    O'Connor, P.2    Soh, C.3    et al4
  • 75
    • 77955363270 scopus 로고    scopus 로고
    • Cappuzzo F, Coudert B, Wierzbicki R, et al. Effcacy and safety of erlotiniib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study (abstr A2.1). 13th World Conference on On Lung Cancer, San Francisco. http://www.2009worldlungcancer.org/. Accessed March 2, 2010.
    • Cappuzzo, F.1    Coudert, B.2    Wierzbicki, R.3
  • 76
    • 77955377009 scopus 로고    scopus 로고
    • Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). (abstr 22LBA). ECCO 15-34th ESMO Multidisciplinary Congress
    • Accessed March 2
    • Cappuzzo F, Coudert B, Wierzbicki R, et al. Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). (abstr 22LBA). ECCO 15-34th ESMO Multidisciplinary Congress, Berlin. http://www.ecco-org.eu/Conferences-and-Events/ECCO-15-ESMO-34/Abstracts-online/page.aspx/1729. Accessed March 2, 2010.
    • (2010) Berlin
    • Cappuzzo, F.1    Coudert, B.2    Wierzbicki, R.3
  • 77
    • 77955403639 scopus 로고    scopus 로고
    • Molecular markers and clinical outcome with erlotinib: Results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC (abstr B9.1) 13th World Conference on On Lung Cancer
    • Available from, Accessed March 2
    • Brugger W, Kim J, Hansen O, et al. Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC (abstr B9.1) 13th World Conference on On Lung Cancer, San Francisco;Available from: http://www.2009worldlungcancer.org/. Accessed March 2, 2010.
    • (2010) San Francisco
    • Brugger, W.1    Kim, J.2    Hansen, O.3
  • 78
    • 77955381104 scopus 로고    scopus 로고
    • Accessed March 2
    • Genetech. Press Release ATLAS study. http://www.genecom/gene/news/press-releases/displaydo?method=detail&id=11827 Accessed March 2, 2010.
    • (2010) Genetech. Press Release ATLAS Study
  • 80
    • 34548484397 scopus 로고    scopus 로고
    • Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    • Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007;58:95-103.
    • (2007) Lung Cancer , vol.58 , pp. 95-103
    • Costa, D.B.1    Kobayashi, S.2    Tenen, D.G.3    Huberman, M.S.4
  • 81
    • 43749107912 scopus 로고    scopus 로고
    • Acquired resistance to tyrosine kinase inhibitors during cancer therapy
    • Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008;18:73-79.
    • (2008) Curr Opin Genet Dev , vol.18 , pp. 73-79
    • Engelman, J.A.1    Settleman, J.2
  • 82
    • 40049099220 scopus 로고    scopus 로고
    • The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
    • Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105:2070-2075.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 2070-2075
    • Yun, C.H.1    Mengwasser, K.E.2    Toms, A.V.3
  • 83
    • 17844390172 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
    • Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23:2556-2568.
    • (2005) J Clin Oncol , vol.23 , pp. 2556-2568
    • Pao, W.1    Miller, V.A.2
  • 84
    • 33751292685 scopus 로고    scopus 로고
    • Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    • Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494-6501.
    • (2006) Clin Cancer Res , vol.12 , pp. 6494-6501
    • Balak, M.N.1    Gong, Y.2    Riely, G.J.3
  • 85
    • 47949114668 scopus 로고    scopus 로고
    • Detection of mutations in EGFR in circulating lung-cancer cells
    • Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366-377.
    • (2008) N Engl J Med , vol.359 , pp. 366-377
    • Maheswaran, S.1    Sequist, L.V.2    Nagrath, S.3
  • 86
    • 21144439000 scopus 로고    scopus 로고
    • Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    • Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102:7665-7670.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 7665-7670
    • Kwak, E.L.1    Sordella, R.2    Bell, D.W.3
  • 87
    • 65249170861 scopus 로고    scopus 로고
    • A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
    • Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15: 2552-2558.
    • (2009) Clin Cancer Res , vol.15 , pp. 2552-2558
    • Wong, K.K.1    Fracasso, P.M.2    Bukowski, R.M.3
  • 88
    • 56349167837 scopus 로고    scopus 로고
    • Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC
    • Janne P, Schellens H, Engelman J, et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol. 2008; 26 Suppl 15:8027.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15 , pp. 8027
    • Janne, P.1    Schellens, H.2    Engelman, J.3
  • 89
    • 56349121456 scopus 로고    scopus 로고
    • Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial
    • Miller V, Wakelee H, Lara P, et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J Clin Oncol. 2008;26 Suppl 15:8028.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15 , pp. 8028
    • Miller, V.1    Wakelee, H.2    Lara, P.3
  • 90
    • 34249075147 scopus 로고    scopus 로고
    • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    • Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043.
    • (2007) Science , vol.316 , pp. 1039-1043
    • Engelman, J.A.1    Zejnullahu, K.2    Mitsudomi, T.3
  • 91
    • 46749156706 scopus 로고    scopus 로고
    • Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    • Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008;118:2609-2619.
    • (2008) J Clin Invest , vol.118 , pp. 2609-2619
    • Guix, M.1    Faber, A.C.2    Wang, S.E.3
  • 92
    • 33750571170 scopus 로고    scopus 로고
    • Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
    • Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006;66:10100-10111.
    • (2006) Cancer Res , vol.66 , pp. 10100-10111
    • Morgillo, F.1    Woo, J.K.2    Kim, E.S.3    Hong, W.K.4    Lee, H.Y.5
  • 93
    • 32944457518 scopus 로고    scopus 로고
    • MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly KE, Rojo F, She QB, et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-1508.
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.B.3
  • 94
    • 76749137179 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
    • Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol. 2010;22: 112-120.
    • (2010) Curr Opin Oncol , vol.22 , pp. 112-120
    • Rosell, R.1    Viteri, S.2    Molina, M.A.3    Benlloch, S.4    Taron, M.5
  • 95
    • 74949110711 scopus 로고    scopus 로고
    • Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    • Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357-360.
    • (2010) J Clin Oncol , vol.28 , pp. 357-360
    • Jackman, D.1    Pao, W.2    Riely, G.J.3
  • 96
    • 74949118501 scopus 로고    scopus 로고
    • Living with imperfection
    • Mok TS. Living with imperfection. J Clin Oncol. 2010;28:191-192.
    • (2010) J Clin Oncol , vol.28 , pp. 191-192
    • Mok, T.S.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.